We are thrilled to announce that Lindus Health has been named a finalist for the prestigious Fierce CRO Award in the category of Outstanding Patient Recruitment and Retention, recognizing our innovative approach to solving one of clinical research's most persistent challenges.
Lindus Health has distinguished itself through its pioneering Patient Identification Center (PIC) technique, which utilizes AI-powered algorithms to identify eligible patients from a database of over 30 million electronic health records. What sets our approach apart is not just the technology, but our deep understanding of how healthcare data is actually recorded and coded by practitioners. Our in-house experts create highly customized searches based on both standard criteria and nuanced knowledge of medical record terminology, significantly improving patient identification accuracy.
The results speak for themselves. In the FLORA trial with Myota, we enrolled prediabetic individuals within strict metabolic parameters in just four months—less than half the projected timeline—while achieving a remarkable 54% screening conversion rate, far exceeding the industry benchmark of approximately 10%. Similarly impressive results have been demonstrated across studies in postpartum depression, severe insomnia, and other therapeutic areas.
The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards honor CROs who display excellence, performance, innovation, and leadership in delivering high-quality research and development services. By recognizing the excellence of CROs, the awards aim to highlight the critical role they play in advancing life sciences research and improving patient outcomes. This recognition underscores our commitment to redefining what modern clinical research should look like, setting a new standard for patient recruitment and retention in the industry.
Click here to view the full list of finalists by category.
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
This collaboration is essential to eliminating traditional barriers in patient recruitment and reducing friction when transitioning between development stages and CRO partners, ultimately accelerating the delivery of breakthrough treatments to patients.
